基于心肌纤维化防治心力衰竭的研究进展

<正>心肌纤维化（myocardial fibrosis,MF）以心脏成纤维细胞增殖和分化、心肌细胞外基质（ECM）过度沉积后，导致间质胶原比例失调和排序紊乱，最终瘢痕形成为特点[1]。MF是心室重构的重要环节，引起心脏结构和功能变化，是终末阶段心力衰竭的病理关键。临床常用的抗心衰药物种类繁多，各类药物在延缓和逆转心室重构方面各有所长。基于此，本文通过梳理MF的可能发病机制，从抗MF角度对各类抗心衰药物进行综述。

Research progress of prevention and treatment of heart failure based on myocardial fibrosis

Myocardial fibrosis is a common pathological change caused by a variety of pathological factors leading to the development of heart disease to a certain stage. It is the main cause of ventricular remodeling and is closely related to a variety of cardiovascular diseases.Heart failure as a serious manifestation and late stage of various heart diseases and has different degrees of ventricular remodeling.In this paper, the possible pathogenesis of myocardial fibrosis is described from the aspects of renin-angiotensin-aldosterone system, cytokines, vascular endothelial active substances, etc., and based on the existing domestic and foreign literatures of anti-heart failure drugs, the aspects of inhibiting myocardial fibrosis to delay and reverse ventricular remodeling are reviewed.